VolitionRx Announces Submission of Manuscript for Nu.Q® Vet Cancer Test in Cats
VolitionRx submitted a clinical manuscript for its Nu.Q Vet Feline test, reporting 86% detection of feline lymphomas with 97% specificity. Publication of the study is expected to unlock a $5 million milestone payment and validates the technology for a new species.
Key figures
- Sensitivity
- 86%
- Specificity
- 97%
- Cancer risk cats
- 1 in 5
- Milestone payment
- $5 million
- Us pet cat population
- 73.8 million
- Us senior cat population
- over 18 million
- Na vet oncology market 2025
- $1.77 billion
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.